Elicio Therapeutics (ELTX) Net Equity Issued and Repurchased (2020 - 2025)

Elicio Therapeutics (ELTX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $2.0 million in Q2 2025.

• Quarterly Net Equity Issued and Repurchased rose 565.35% year-over-year to $2.0 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.0 million (down 83.49% YoY) and the FY2025 annual result came in at $16.2 million, up 256.62% from the prior year.
• Net Equity Issued and Repurchased climbed to $2.0 million in Q2 2025, from $835000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $110.6 million in Q1 2021 to a low of -$3.1 million in Q4 2021.
• A 5-year average of $11.9 million and a median of $1.6 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased jumped 12392.66% — and 2024, when it slumped 112.26%.
• Tracing ELTX's Net Equity Issued and Repurchased over 5 years: stood at -$3.1 million in 2021, then soared by 461.57% to $11.1 million in 2022, then sank by 37.01% to $7.0 million in 2023, then tumbled by 112.26% to -$858000.0 in 2024, then soared by 334.97% to $2.0 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $2.0 million (Q2 2025), $835000.0 (Q1 2025), and -$858000.0 (Q4 2024), per Business Quant data.